{Fig. 1} Spontaneous formation of vascular networks upon implantation of Microtissue SVF with regenerative cells into fibrin to simulate the natural soft tissue wound environment

About Us

Liporegena GmbH is an Austrian company with the focus on the development, manufacture and approval of highly efficient mechanical devices for the standardized isolation and medical application of autologous adipose-derived regenerative cells in the form of Microtissue.

Background

Adipose tissue is an attractive and abundant source of stem cells for regenerative medicine and tissue engineering. In particular, the regenerative effect of “stromal vascular fraction” (SVF, a heterogeneous cell mixture rich in adipose-derived stem cells) has been proven in numerous clinical studies.

SVF has so far generally been isolated from liposuction material by an enzymatic procedure leading to single isolated cells.
Keeping the cells in their natural niche with the SVF-Microtissue approach (Nürnberger et al. Eur Cell Mater. 2019 doi: 10.22203/eCM.v037a08) further improves regenerative capacity. Various systems from different suppliers have been launched during the past years allowing the physicians to isolate SVF in around 90 minutes in with the use of an incubator and a centrifuge. Collagenase derived SVF was therapeutically used primarily by plastic surgeons and dermatologists, to a certain degree by orthopaedists.

Liporegena enables
non enzymatic isolation of SVF

However, the use of enzymes in the isolation of SVF has most recently been questioned by the health authorities, since it is considered more than “minimal manipulation” and such considered as ATMP (Advanced Therapy Medicinal Product) with high registration costs. A full investigation of the enzymes effect on cells is not available and negative effects cannot be excluded.
In contrast, Liporegena’s novel patented Microtissue technology enables closed, sterile, non enzymatic isolation of SVF for autologous clinical applications such as tissue reconstruction, repair or replacement in a total of less than 30 minutes.

Medical Use

SVF has been used in different clinical indications such as hair loss (alopecia), wound healing, and autologous fat transplantation. The clinical effect has so far been described by numerous published case studies and by a general understanding of the medical community. However, only very few publications describe randomized, controlled clinical studies. Therefore, it is one of the goals of Liporegena, to use its standardized method for SVF isolation and initiate clinical trials with a sufficient statistical power to also support medical claims with scientific data.

Microtissue

Stem cells, which are embedded in the Microtissue, can easily adapt to the local tissue environment in in-vivo situations. Depending on the environment the Microtissue supports for example chondrogenic spheroid formation (Fig 2) or soft tissue regeneration, the latter by angiogenesis and vascular network formation (Fig 1). Due to this ability, stem cells have substantial advantages over other medical procedures and treatments.

Why Microtissue?

{Fig. 2} Difference in increase in chondrogenic differentiation and pellet/spheroid formation (size on y-axis) over 35 days of pellet incubation (x-axis)based upon cells from Microtissue preparations either from mechanical fast Microtissue procedure (lower pellet – Azian staning) or the standard collagenase based SVF isolation (upper pellet).

Liporegena´s Microtissue technology represents a method which is mild, fast and cost-effective

Several commercial non-enzymatic systems for isolation of regenerative cells from autologous fat have become available recently. While such systems aim to provide a safe and reproducible cell isolation process, many are still based on enzymatic digestion with collagenase in addition to mechanical homogenization of the adipose tissue, which is expensive, time consuming, may have negative impacts on cell potency and efficacy, and complicates regulatory authorization. Other systems provide simple mechanical procedures, leading to a reduced number of cells or damaged cells with a limited cell viability.

In contrast Liporegena´s Microtissue technology represents a non-enzymatic isolation method which is mild, fast and cost-effective. The closed, sterile Microtissue isolation set (single use) is operated by a fully automated processing unit and a standard centrifuge. Thus, this system allows safe and efficient intraoperative isolation of SVF within less than 30 minutes and yields regenerative cells in comparable quantity and even superior quality to the traditional enzymatic method. In particular, cells isolated using Liporegena´s Microtissue technology show significantly higher viability and metabolic activity in contrast to enzymatically isolated cells. In addition, these cells show significantly stronger differentiation towards fat, bone, or cartilage (Fig2) depending on environmental conditions.

Cooperation